Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 13, 2013
WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 13, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented during ObesityWeekSM 2013, hosted by The Obesity Society and the Americ...
Nov 7, 2013
SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2013. Arena has also rescheduled its conference call and webcast to tomorrow, November 8, 2013, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). "We a...
Nov 7, 2013
SAN DIEGO, Calif. and WOODCLIFF LAKE, N.J., Nov. 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. along with its ...
Oct 30, 2013
SAN DIEGO, Oct. 30, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and report third quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, November 7, 2013. That same day, Arena will host a conference call and webcast at 5:00 p.m. Eastern Time...
Oct 15, 2013
SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. will increase its BELVIQ® sales force to approximately 400 representatives by December 2013, doubling the size of the sales force from when BELVIQ became available in June 2013. The expansion of the sales force, which has c...
Sep 23, 2013
SAN DIEGO, Sept. 23, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview, including a BELVIQ® (lorcaserin HCl) CIV launch update, at the NewsMakers in the Biotech Industry conference on Friday, September 27, 2013, at 11:30 a.m. Eastern Time (8:30 a.m. Pac...
Sep 18, 2013
SAN DIEGO, Sept. 18, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)Barcelona, Spain: September...
Sep 16, 2013
SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided an update on Eisai Inc.'s marketing activities for BELVIQ® (lorcaserin HCl) as the US launch campaign enters its consumer phase. Beginning this month, full-page announcements communicating the availability of BELVIQ are being placed in ma...
Sep 6, 2013
SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference on Friday, September 13, 2013, at 1:45 p.m. British Summer Time (5:45 a.m. Pacific Time), at the Bank of America Merrill L...
Aug 28, 2013
SAN DIEGO, Aug. 28, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin (IP) receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH). The company plans to initiate a Phase 2 clinical trial for APD811 ...
Aug 1, 2013
SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2013. "We are very encouraged by the positive response from patients and physicians since BELVIQ became available in US pharmacies on June 11," said Jack Li...
Jul 25, 2013
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that BELVIQ® (lorcaserin HCl) has been nominated for the 2013 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults. The Pr...
Jul 25, 2013
SAN DIEGO, July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement with CY Biotech Company Ltd. (CYB) for BELVIQ® (lorcaserin HCl) in Taiwan. Under the agreement, Arena granted CYB the righ...
Jul 24, 2013
SAN DIEGO, July 24, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and report second quarter 2013 financial results before the NASDAQ Global Select Market opens on Thursday, August 1, 2013. That same morning, Arena will host a conference call and webcast at 8:30 a.m. Eastern T...
Jun 26, 2013
SAN DIEGO, June 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission (NDS) for BELVIQ™ (lorcaserin HCl) with Health Canada. BELVIQ is being evaluated in Canada as an adjunct to a reduced-calorie di...
= add release to Briefcase